Getein Biotech (SHSE:603387) Total Long-Term Assets: ¥1,209 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603387 Getein Biotech Inc SHSE:603387
79 GF Score
Price ¥9.42
GF Value ¥7.95
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Getein Biotech Total Long-Term Assets?

Getein Biotech SHSE:603387 +0.96% 79 Total Long-Term Assets is ¥1,209 Mil as of Jun. 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 79/100 and a GF Value™ of ¥7.95 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Getein Biotech's Total Long-Term Assets for the quarter that ended in Jun. 2026 was ¥1,209 Mil.

Getein Biotech Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Getein Biotech's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Getein Biotech Total Long-Term Assets Chart

Getein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 772.51 1,279.54 1,620.44 1,850.33 1,453.25

Getein Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,588.70 1,543.34 1,453.25 1,380.47 1,209.22
SHSE:603387
79GF Score
Getein Biotech Inc SHSE:603387
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Getein Biotech Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ¥1,209 Mil mean?
Getein Biotech (SHSE:603387) has a Total Long-Term Assets of ¥1,209 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Getein Biotech and its competitors.
Is Getein Biotech's Total Long-Term Assets too high?
Getein Biotech's current Total Long-Term Assets is ¥1,209 Mil. Overall, Getein Biotech has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Total Long-Term Assets compare to ABT and SYK?
Getein Biotech's Total Long-Term Assets of ¥1,209 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Getein Biotech and its competitors. Getein Biotech's current Total Long-Term Assets is ¥1,209 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.95, compared to a current price of ¥9.42 — trading 18.5% above its estimated fair value. The current Total Long-Term Assets is ¥1,209 Mil. Getein Biotech's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Total Long-Term Assets is ¥1,209 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Getein Biotech (SHSE:603387) Overvalued in 2026?

Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued. The current stock price of ¥9.42 is trading 18.5% above its estimated GF Value™ of ¥7.95. GuruFocus considers Getein Biotech to be Modestly Overvalued.

Key valuation signals for SHSE:603387:

  • Total Long-Term Assets: ¥1,209 Mil
  • GF Value™: ¥7.95 vs. price of ¥9.42 (18.5% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Getein Biotech Business Description

Address No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
79GF Score

Get the complete analysis for SHSE:603387

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.42
Price
¥7.95
GF Value